Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Editas Competitor CRISPR Therapeutics Hails European Patent Decision

Executive Summary

CRISPR Therapeutics says its IP position has been reinforced by the European Patent Office's aim to grant the University of California patent recognition covering CRISPR gene-editing for non-cellular and cellular use.

You may also be interested in...



Editas' EDIT-101 Set To Be First In Vivo CRISPR Gene-Editing Therapy In Clinic

Editas CEO says recent IND filing to treat LCA10 eye disease puts EDIT-101 on track to be first CRISPR medicine administered directly to patients. Bosley also voices relief at recent US IP court ruling.

India’s Stem Cell Guidelines Mandate Additional Checks

Draft update to national guidelines factors in additional safeguards and makes it mandatory to establish institutional panels to review stem cell research. Gene editing would be an area of "restrictive" research.

Merck Develops 'New And Improved' CRISPR

Merck of Germany has developed a new genome editing tool that it believes improves on the popular, but IP battle-worn, CRISPR technology. How this will affect the existing IP landscape is as yet unknown.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1125347

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel